AVTX
Avalo Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Avalo Therapeutics, Inc.
7.16
−0.29 · −3.83%
post 7.16 0.00%
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $94.3M | 7.12% | +77.12% | |
| 2 | BlackRockBlackRockindex-like | $80.7M | 6.09% | +1234.70% | |
| 3 | Deep Track CapitalDeep Track Capital | $66.7M | 5.04% | new | |
| 4 | Caligan PartnersCaligan Partners | $58.5M | 4.41% | +93.51% | |
| 5 | TCG Crossover ManagementTCG Crossover | $55.8M | 4.21% | +308.61% | |
| 6 | Affinity Asset AdvisorsAffinity Asset | $53.6M | 4.05% | +116.28% | |
| 7 | State StreetState Streetindex-like | $53.4M | 4.03% | +3932.28% | |
| 8 | Farallon Capital ManagementFarallon | $46.2M | 3.49% | new | |
| 9 | Point72 Asset ManagementPoint72 | $44.1M | 3.33% | +160.55% | |
| 10 | venBio Select AdvisorvenBio Select Advisor | $43.1M | 3.26% | +65.48% | |
| 11 | Vanguard Capital ManagementVanguardindex-like | $41.8M | 3.16% | +214.61% | |
| 12 | BVFBVF | $38.4M | 2.90% | +27.11% | |
| 13 | Bank of AmericaBank of America | $35.4M | 2.67% | +197.64% | |
| 14 | Nantahala Capital ManagementNantahala | $34.4M | 2.60% | +50.79% | |
| 15 | Adage Capital Partners GPAdage Capital Partners GP | $32.0M | 2.41% | +102.46% | |
| 16 | Soleus Capital ManagementSoleus | $30.6M | 2.31% | +274.45% | |
| 17 | BraidwellBraidwell | $30.1M | 2.27% | new | |
| 18 | T. Rowe Price AssociatesT. Rowe Price | $24.2M | 1.83% | new | |
| 19 | AlliancebernsteinAlliancebernstein | $23.3M | 1.76% | new | |
| 20 | UBS GroupUBS | $22.3M | 1.69% | +5.87% | |
| 21 | Logos Global ManagementLogos Global | $21.3M | 1.60% | −11.54% | |
| 22 | Geode Capital ManagementGeodeindex-like | $20.4M | 1.54% | +550.49% | |
| 23 | Commodore CapitalCommodore Capital | $18.8M | 1.42% | +110.83% | |
| 24 | RA Capital ManagementRA Capital Management | $18.5M | 1.40% | +50.84% | |
| 25 | Goldman Sachs GroupGoldman Sachs | $17.5M | 1.32% | +1474.42% |
127 managers report $1.3B of Avalo Therapeutics on form 13F for the quarter ended Jun 30 '26. 29 of them hold 80% of it; FMR is largest at 7.12%.
Linked news
Expected move
Inputsstraddle ±18.7%
spot 7.17exp Nov 20ATM strike 7.5ATM straddle 1.58IV 111%